PLX-61639 vs PRT3789
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: SMARCA2 · full Non-Small Cell Lung Cancer pipeline
PLX-61639
Developed by Plexium, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
PRT3789
Developed by Prelude Therapeutics
NCT05639751 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Dose limiting toxicity (DLT) of PRT3789 monotherapy and in combination with docetaxel (Baseline through Day 21); Safety and tolerability of PRT3789 monotherapy and in combination with docetaxel: AEs, CTCAE Assessments (Baseline through approximately 3 years); Maximum tolerated dose (MTD)/ Recommended phase 2 dose (RP2D) of PRT3789 monotherapy and in combination with docetaxel (Baseline through approximately 3 years): PRT3789 (SMARCA2 degrader): well tolerated through 8 cohorts, no DLTs identified, no MTD reached; 3 confirmed PRs and 7/26 with tumor shrinkage in heavily pretreated NSCLC/esophageal patients (Aug 2024 data cutoff, 65 safety-evaluable)
Result source: NCT05639751
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | PLX-61639 | PRT3789 |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- PLX-61639
- —Not reported
- PRT3789
- —Not reported
OS, median
- PLX-61639
- —Not reported
- PRT3789
- —Not reported
ORR
- PLX-61639
- —Not reported
- PRT3789
- —Not reported
Duration of response, median
- PLX-61639
- —Not reported
- PRT3789
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
PLX-61639: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PLX-61639's landscape · PRT3789's landscape